文献速递头颈部肿瘤放疗姑息放疗与转移瘤

度伐利尤单抗联合替西木单抗与立体定向放疗治疗转移性头颈癌的1/2期试验

Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-12

这项多机构1/2期研究评估了替西木单抗(T)和度伐利尤单抗(D)联合立体定向体部放疗(SBRT)在寡转移头颈鳞癌中的安全性和疗效。6个月无进展生存(PFS)率为72.7%,中位PFS为12.8个月,中位总生存为28.4个月,双免疫联合SBRT耐受良好,达到安全性和主要终点。

要点

  • 双免疫联合SBRT在寡转移头颈鳞癌中耐受良好,6个月PFS率达72.7%。
  • 中位PFS为12.8个月,中位总生存为28.4个月。
  • 7例(21%)患者发生与D和T相关的3-4级不良事件,1例因SBRT发生5级不良事件。

核心结论

  • 双检查点抑制联合SBRT耐受良好,6个月PFS结果令人鼓舞,达到安全性和主要终点。

主要发现

  • 中位PFS为12.8个月(95% CI, 7.17-27.2),6个月PFS率为72.7%(95% CI, 59.0-89.6)。
  • 中位总生存为28.4个月(95% CI, 22.9-38.9)。
  • 7例(21%)患者发生与D和T相关的3-4级不良事件;1例因SBRT发生5级不良事件(黏膜再照射后放射性坏死)。
  • 患者既往接受1、2、3线系统治疗的比例分别为48%、21%、9%。
  • SBRT中位剂量为45 Gy(范围18-50 Gy),分3-5次。

关键数值与推荐

  • SBRT处方剂量中位45 Gy(范围18-50 Gy),分3-5次,照射2-5个病灶。
  • 度伐利尤单抗1500 mg联合替西木单抗75 mg,每4周一次共4周期,随后度伐利尤单抗单药治疗8周期。

临床怎么用

  • 对于寡转移头颈鳞癌,可考虑双免疫联合SBRT作为治疗选择,但需注意SBRT相关严重不良事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This multi-institutional phase 1/2 study evaluated the safety and efficacy of tremelimumab (T) and durvalumab (D) in combination with stereotactic body radiation therapy (SBRT) in oligometastatic head and neck squamous cell carcinoma (ClinicalTrials.gov identifier: NCT03283605). METHODS AND MATERIALS: Patients with oligometastatic head and neck squamous cell carcinoma (2-10 lesions) received D (1500 mg) and T (75 mg) for 4 monthly cycles, followed by D monotherapy for an additional 8 monthly cycles. SBRT was administered to 2 to 5 lesions during cycle 2. In phase 1, the primary endpoint was safety, whereas in phase 2, the primary endpoint was 6-month progression-free survival (PFS). Secondary endpoints included local control, out-of-SBRT field objective response rate, and overall survival. RESULTS: Thirty-three evaluable patients were recruited (accrual interrupted by COVID-19). Patients had received 1, 2, and 3 prior lines of systemic therapy in 48%, 21%, and 9% of cases, respectively. The median SBRT dose was 45 Gy (range, 18-50) in 3 to 5 fractions. There were 9 Grade 3 to 4 AEs related to D and T, occurring in 7 (21%) patients. One patient experienced a Grade 5 AE due to SBRT (radionecrosis following mucosal reirradiation); no other Grade 3 to 5 AEs were attributed to SBRT or the SBRT-immunotherapy combination. Median PFS was 12.8 months (95% CI, 7.17-27.2) with a 6-month PFS of 72.7% (95% CI, 59.0-89.6), whereas median overall survival was 28.4 months (95% CI, 22.9-38.9). CONCLUSIONS: Dual-checkpoint inhibition combined with SBRT was well tolerated and led to promising 6-month PFS, meeting both safety and primary endpoints.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bahig H, Ye RZ, Aubin F, et al. Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma. Int J Radiat Oncol Biol Phys. 2026. PMID: 42586218. doi:10.1016/j.ijrobp.2026.07.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。